Redbiotec is a privately held Swiss Biopharmaceutical Company, based in Zurich-Schlieren. Founded in 2006 as a spin-off of the ETH Zurich, the company won several awards, including the renown W.A. De Vigier award.
Redbiotec uses its proprietary rePAX® co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. The company entered the field of VLP vaccines in 2008 and currently has a pipeline in the areas of CMV, HPV and Influenza. Besides developing its own prophylactic VLP vaccine pipeline, the company also offers customized solutions in Biologics to selected Partners.
Redbiotec is backed by experienced institutional and private investors.